register

Medical

National consultation to set MRFF medical research priorities

Health Industry Hub | September 16, 2020 |

Medical News: A national consultation process will guide the third set of the Morrison Government’s ground-breaking Medical Research Future Fund (MRFF) Australian Medical Research and Innovation Priorities for 2020–2022.

This consultation process will ensure the MRFF continues to target national health priorities for better health outcomes.

Nadia Levin, CEO and Managing Director said “With the MRFF reaching full capitalisation of $20 billion this year, it plays as key funding role for all stages of Australian health and medical research. As we have throughout the history of MRFF, Research Australia will be engaging closely in the development of the next set of priorities to ensure that all stages of the medical research pipeline can benefit. It will be central to growing our sector and positioning Australia as a global leader in health and medical research and innovation.”

Determining future health priorities is about taking into account the burden of disease in Australians and the need to enhance the translation of research into clinical practice.

Australia’s health and medical researchers are world class and the Government continues to drive investment in ways that deliver the practical benefits of medical research and innovation to all Australians.

The landmark $20 billion MRFF is enhancing this growth in Australia’s cutting-edge health and medical research.

Join 22,000+
industry professionals
in accessing the latest 
industry news, scientific insights & engaging professional development 
content from
Health Industry HubTM, 
the ONLY one-stop-hub
connecting Australia’s 
Pharma, MedTech & Biotech
industry professionals. Register now.

It is leading to new cures and treatments across Australia—saving lives and improving lives. The Australian public, organisations with expertise in health and medical research and innovation, consumer representatives, clinicians and health services managers are invited to contribute to the consultation.

Consultation is now open to inform the development of the Medical Research Future Fund (MRFF) Australian Medical Research and Innovation Priorities for 2020–22.

The Australian Medical Research Advisory Board is seeking comment from interested parties through online submissions and public webinars until 7 October 2020.

Visit the Department of Health’s Consultation Hub to see how you can comment online.


News & Trends - MedTech & Diagnostics

Health insurers clash with government decision on GUIs, prompting threat of premium hikes

Health insurers clash with government on GUIs decision, prompting threat of premium hikes

Health Industry Hub | May 2, 2024 |

MedTech & Diagnostics News: A warning of potential increases in health insurance premiums for 15 million Australians has been issued […]

More


News & Trends - MedTech & Diagnostics

Catheter ablation underused in atrial fibrillation despite proven efficacy

Catheter ablation underused in atrial fibrillation despite proven efficacy

Health Industry Hub | May 2, 2024 |

MedTech & Diagnostics News: A new study highlights that nearly half of all patients hospitalised for atrial fibrillation (AF) in […]

More


News & Trends - Biotechnology

How prepared are we for the next pandemic?

How prepared are we for the next pandemic?

Health Industry Hub | May 2, 2024 |

Biotech News: The Melbourne biotechnology community came together for a symposium hosted by BioMelbourne and mRNA Victoria, featuring specialists in […]

More


News & Trends - Pharmaceuticals

AbbVie's JAK inhibitor triumphs: Head-to-Head trial reveals superior outcomes in atopic dermatitis

AbbVie’s JAK inhibitor triumphs: Head-to-Head trial reveals superior outcomes in atopic dermatitis

Health Industry Hub | May 2, 2024 |

Pharma News: In a head-to-head trial, AbbVie’s JAK inhibitor Rinvoq (upadacitinib) showed superior efficacy over Regeneron and Sanofi’s Dupixent (dupilumab) […]

More


This content is copyright protected. Please subscribe to gain access.